Iovance Biotherapeutics, Inc.

Contributing Author

Recent Articles by Iovance Biotherapeutics, Inc.

Jul-24	Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025 IOVA GlobeNewswire
Jul-18	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA GlobeNewswire
Jul-15	Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer IOVA GlobeNewswire
Jul-14	Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi in Patients with Advanced Melanoma IOVA GlobeNewswire
Jul-10	Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy IOVA GlobeNewswire
Jun-23	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA GlobeNewswire
Jun-10	Iovance Biotherapeutics to Present at Upcoming Conference IOVA GlobeNewswire
Jun-02	The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi (lifileucel) in Patients with Advanced Melanoma IOVA GlobeNewswire
May-22	Iovance Announces Five-year Results of Amtagvi (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting IOVA GlobeNewswire
May-16	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA GlobeNewswire
May-08	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 IOVA GlobeNewswire
May-02	Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025 IOVA GlobeNewswire